Ellebaek, E., Weichenthal, M., Gavrilova, I., Asher, N., Terheyden, P., Utikal, J., Suljeviić, A.J., Pföhler, C., Stojkovski, I., Herbst, R.A., Ugurel, S., Ruhlmann, C., Berrocal, A., Majem, M., Dujovic, B., Šabarić, V., Duvancic, T., Soria, A., Donia, M., Schmidt, H., Friis, R.B., Gerasimov, A., Shalamanova-Deleva, G., Kontilev, A., Lev-Ari, S., Shapira, R., Piccin, L., Minisini, A., Özdemir, B.C., Teterycz, P., Mariuk-Jarema, A., Ziogas, D., Anastasopoulou, A., Stefanou, D., Gutiérrez, L., Gebhardt, C., Dummer, R., Hauschild, A., Mohr, P., von Wasielewski, I., Meier, F., Haanen, J., Svane, I.M., Ascierto, P.A., Mangana, J., Rutkowski, P., Gogas, H., Bastholt, L. & Schadendorf, D. (2026). Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study. EJC Skin Cancer, 4: 100773. Elsevier. doi:10.1016/j.ejcskn.2025.100773.